Replies to post #35267 on China Growth Stocks

[BiotechValues]

bunky

Should be about 49M I think.

Another positive about LTUS that I never see mentioned is their ability to collect AR balances and their lower DSO than insutry average (I'll try to get their DSO number...but I remember it being very favorable)

They had nearly $40M in sales for the first 9 months of 2009, and only $1.7M in accounts receivable, with $15.5M in positive cash flow for that time period. Compared to ALL other China pharma's I know, LTUS beats them in terms of effective collections.